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Background: To date, the significance of altered expression of V-set and immunoglobulin domain containing 1 (VSIG1) in gastric cancer has
not yet been elucidated.
Methods: We examined VSIG1 expression in 30 paired gastric cancer tissues and noncancerous gastric mucosa as well as in 5 gastric cancer
cell lines by real-time PCR and Western blotting. In addition, we analyzed VSIG1 expression in 232 gastric adenocarcinoma samples by
immunohistochemistry.
Results: VSIG1 expression was significantly reduced at both the mRNA and protein levels in gastric cancer tissues. Immunohistochemistry
revealed that VSIG1 expression was completely lost in 126 out of the 232 (54.3%) patient samples and remarkably reduced in another 106
(45.7%) patients. Negative VSIG1 expression was significantly correlated with tumor size (P ¼ 0.007), T (P ¼ 0.023), and M stage
(P ¼ 0.037). Importantly, loss of VSIG1 expression was significantly correlated with poor overall survival (OS, P < 0.001) and disease-free
survival (DFS, P ¼ 0.006) in gastric cancer patients. Cox regression analyses showed that VSIG1 expression was an independent predictor of
OS (P ¼ 0.002) and DFS (P ¼ 0.039).
Conclusions: Our findings suggest that silencing VSIG1 may play an important role in gastric carcinogenesis and that VSIG1 may serve as a
prognostic marker as well as a potential therapeutic target for gastric cancer.
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INTRODUCTION
Gastric cancer is the fourth most common malignancy in the
world and the second leading cause of cancer-related death in
humans [1]. Nearly one million new gastric cancer cases are diag-
nosed each year worldwide, half of which are in Eastern Asia. It is
generally thought that gastric cancer results from the combinatorial
effects of environmental factors and the accumulation of genetic and
epigenetic disorders. Most gastric cancers emerge after a long period
of chronic atrophic gastritis and intestinal metaplasia, with the single
most common cause being Helicobactor pylori infection [2]. In addi-
tion, the consumption of grilled and N-nitrosamine-enriched foods is
also considered to be highly correlated with gastric carcinogenesis.
When clinically diagnosed, a significant number of gastric cancer
patients are beyond the limits of curative resection [3]. Understand-
ing the molecular pathways involved in gastric carcinogenesis will
be critical for the improvement of diagnosis and therapy of gastric
cancer.
Aberrant gene expression, including the activation of oncogenes
and the inactivation of tumor suppressor genes, plays an important
role in the initiation and progression of gastric cancer [4]. Thousands
of genes differentially expressed between normal gastric mucosa and
cancerous tissues, including those that mediate cell adhesion, have
been identified using high-throughput microarray-based expression
profiling [5,6]. Cell adhesion molecules participate in numerous cell
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functions, for example, signal transduction, cell growth, differentia-
tion, cell motility, and immune function [7]. In fact, changes in
the expression and function of cell adhesion molecules have been
implicated in all steps of tumor development and progression. These
disorders cause disruption of cell–cell or cell–extracellular matrix
interactions, which significantly contribute to the uncontrolled
proliferation, progression, and metastasis of cancer cells. One of the
classical examples is E-cadherin, a calcium-dependent cell adhesion
glycoprotein encoded by the CDH1 gene, which has been shown
to be exclusively expressed in epithelia and frequently silenced
in carcinoma, including gastric cancer [8–10]. In contrast, over-
expression of integrin b3 is correlated with poor prognosis of gastric
cancer [11].
Increasing attention has recently been paid to the role of tight
junctions in carcinogenesis. Tight junctions are a characteristic
feature of epithelial cells and are constructed from a complex array
of integral and peripheral proteins [12]. The former include occludin,
tricellulin, claudins, junctional adhesion molecules (JAMs) and
Crumbs, whereas the latter comprise a wide spectrum of proteins,
including the membrane-associated guanylate kinase (MAGUK) fam-
ily, MAGUK inverted (MAGI) proteins, cingulin and symplekin.
Two major functions defined for tight junctions are the regulation of
paracellular permeability and the maintenance of cell polarity. The
development of epithelial tumors is associated with a loss of cell
polarity and disturbances in the structure and function of tight
junctions. The down-regulation of JAM-A has been reported to be
involved in the progression of clear cell renal cell carcinoma [13]
and breast cancer cells [14], whereas JAM-C promotes tumor growth
and angiogenesis [15]. In gastric cancer, decreased expression of
claudins-1, 4, and 11 is associated with a more malignant cancer
phenotype [16–18], while the expression of claudin-7 is increased in
intestinal-type gastric cancer [19] and may cause epithelial dysfunc-
tion [20]. Coxsakievirus and adenovirus receptor (CAR), another
member of the JAM family, has been reported to suppress the prolif-
eration, migration, and invasion of gastric cancer cells, and the loss
of CAR predicts poor prognosis in gastric cancer [21]. Overall, these
observations underline the complex roles of tight junction proteins in
gastric cancer.
V-set and immunoglobulin domain containing 1 (VSIG1), a newly
discovered member of the JAM family, is widely expressed in
gastric epithelia [22]. A recent microarray study showed that
VSIG1 expression was reduced in both Japanese and Finnish
gastric cancer tissues [23]. However, the clinical significance of such
differential expression and the function of the VSIG1 protein have
not yet been defined. In this study, we evaluated the expression of
VSIG1 using quantitative real-time PCR, Western blotting, and
immunohistochemistry. We determined its correlation with clinico-
pathological parameters. In addition, we identified the potential
prognostic value of VSIG1 for the post-resection survival of gastric
cancer patients.




All 232 106 126
Age (years)
<55 121 61 60 2.274 0.132
55 111 45 66
Gender 1.739 0.187
Female 73 38 35
Male 159 68 91
Tumor size (cm) 7.236 0.007
<3 29 20 9
3 203 86 117
T stage 9.496 0.023
T1 17 13 4
T2 20 12 8
T3 183 76 107
T4 12 5 7
N stage 5.586 0.134
N0 60 32 28
N1 99 45 54
N2 49 23 26
N3 24 6 18
M stage 4.331 0.037
M0 214 102 112
M1 18 4 14
Grade 0.578 0.749
1 4 2 2
2 42 17 25
3 186 87 99
Locus 7.004 0.072
Cardia and fundus 84 32 52
Corpus 36 19 17
Antrum 87 47 40
Other sitesb 25 8 17
VSIG1, V-set and immunoglobulin domain containing 1.
a
Numbers of cases in each group.
b
Mainly remnant gastric cancer.
Statistically significant (P < 0.05).
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MATERIALS AND METHODS
Patients and Follow-Up
The clinicopathological data from 232 gastric cancer patients who
underwent surgical resection at the Sun Yat-Sen University Cancer
Center between 2003 and 2006 were retrospectively analyzed.
Patients who met all the following eligibility criteria were included
in our study: (1) diagnosis of gastric adenocarcinoma identified by
histopathological examination; (2) surgical history that included gas-
trectomy plus lymphadenectomy (limited or extended); (3) availabili-
ty of complete follow-up data; (4) no preoperative treatment, such as
chemotherapy and radiotherapy; (5) no history of familial malignan-
cy or other synchronous malignancy; (6) no recurrent gastric cancer,
and (7) no death during the perioperative period. Tumor resection
and D2 lymphadenectomy were performed by experienced surgeons,
and the surgical procedure of radical resection, following the Japa-
nese Gastric Cancer Association (JGCA) guidelines [24], was similar
in all patients. These patients included 159 males and 73 females,
with a median age of 59 years (range: 23–85 years). Gastric cancer
was primarily diagnosed by imaging (X-ray, CT, MRI, etc.), endos-
copy, and biopsy. After operation, histopathological diagnosis of
each tumor specimen was confirmed with hematoxylin–eosin (HE)
staining in the Department of Pathology. The histopathological type
and grade were determined using the criteria of the World Health
Organization (WHO) classification [25]. All the gastric adenocarci-
nomas were graded based on their glandular differentiation degree,
with Grade 1 for well-differentiated adenocarcinomas (more than
95% of tumor composed of glands), including tubular adenocarcino-
mas; Grade 2 for moderately differentiated adenocarcinomas (50–
95% of tumor composed of glands), and Grade 3 for poorly differen-
tiated carcinomas (49% or less of tumor composed of glands). All
patients were staged according to the seventh-edition Tumor Node
Metastasis (TNM) staging system of the Union for International Can-
cer Control (UICC) and American Joint Committee on Cancer
(AJCC) [26]. Post-operative follow-up, including physical and labo-
ratory examinations, was performed at the outpatient department
every 3 months for the first 2 years, every 6 months for the 3rd to
5th years and annually thereafter until at least 5 years after the oper-
ation or until the patient died, whichever came first. The follow-up
was closed in September, 2011. The median follow-up for the entire
cohort was 57 months (range: 3–91 months). Overall survival (OS),
defined as the time from operation to death or last follow-up, was
used as a measure of prognosis. Disease-free survival (DFS) is de-
fined as the time elapsed from operation to the date of the recurrence
or distant metastasis of gastric cancer (with histopathological
confirmation or imaging diagnostic evidence of tumor recurrence or
metastasis); development of a second nongastric cancer (with
the exception of skin basal cell carcinoma; ductal or lobular breast
carcinoma in situ and cervical carcinoma in situ), or death, whichever
occurred first. The characteristics of these patients are listed in
Table I.
Gastric Cancer Tissues
For real-time quantitative PCR and Western blotting analyses, a
total of 30 paired cancerous tissues and matched adjacent noncancer-
ous gastric mucosa located at least 2 cm away from the cancer were
collected from gastric adenocarcinoma patients undergoing gastrecto-
my at Sun Yat-Sen University Cancer Center between March and
June, 2009. The 30 patients included 19 men and 11 women, with a
median age of 53 years (range: 31–77 years). After resection, the
fresh tissues were immediately frozen in liquid nitrogen and stored
at 808C. Both the cancerous and noncancerous gastric mucosa
tissues were verified by histopathological examination. For immuno-
histochemical staining, formalin-fixed, paraffin-embedded primary
gastric adenocarcinoma samples were collected from the 232 patients
mentioned above and stored at room temperature. HE slides from
these patients were viewed under a light microscope by a pathologist
and 5-mm thick tissue sections were cut from corresponding blocks
containing representative tumor regions. The research was approved
by the Ethical Committee of Sun Yat-Sen University Cancer Center,
and informed consent was obtained from each patient.
Cell Culture
Gastric cancer cell lines SGC7901, MGC803, HGC27, MKN45,
and AGS were obtained from the Committee of Type Culture Collec-
Fig. 1. Decreased VSIG1 mRNA expression in gastric cancer tis-
sues as assessed by real-time quantitative PCR (n ¼ 30, P ¼ 0.021).
Fig. 2. Decreased VSIG1 protein expression in gastric cancer as
assessed by Western blotting. A: Relative VSIG1 protein expression
levels in gastric cancer tissues and noncancerous tissues (VSIG1/
GAPDH, n ¼ 26, P ¼ 0.033). Horizontal lines represent the mean.
B: Representative VSIG1 protein expression in four paired gastric
cancer and noncancerous mucosa (C, gastric cancer tissues; N,
matched noncancerous gastric mucosa). C: Loss of VSIG1 expres-
sion in five gastric cancer cell lines.
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tion of Chinese Academy of Sciences (Shanghai, China) and cultured
in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine
serum at 378C with 5% CO2.
RNA Extraction and Quantitative Real-Time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen, Carls-
bad, CA) according to the manufacturer’s protocol. Then, 2 mg of
RNA was reverse transcribed into first-strand cDNA by M-MLV Re-
verse Transcriptase (Promega, Madison, WI) according to the manu-
facturer’s instructions. VSIG1 and GAPDH were amplified by
quantitative real-time PCR using the following primers: VSIG1 for-
ward: 50-GATTGGTAGCCTGGTAGGTGCC-30, reverse: 50-CCGC-
GATGGTCTTAGAATTTCT-30; GAPDH forward: 50-CTCCTCCTG-
TTCGACAGTCAGC-30, reverse: 50-CCCAATACGACCAAATCCG-
TT-30. Gene-specific amplification was performed in an ABI 7900HT
real-time PCR system (Life Technologies, Carlsbad, CA) with a 15-
ml PCR mix containing 0.5 ml of cDNA, 7.5 ml of 2 SYBR Green
master mix (Invitrogen), and 200 nM of the appropriate primers. The
mix was preheated at 958C for 10 min and then amplified in 45
cycles of 958C for 30 sec and 608C for 1 min. The resolution curve
was measured at 958C for 15 sec, 608C for 15 sec, and 958C for
15 sec. The Ct (threshold cycle) value of each sample was calculat-
ed, and the relative expression of VSIG1 mRNA was normalized to
the GAPDH value (2DCt method).
Western Blotting Analysis
Homogenized tissues were lysed in RIPA lysis buffer, and the
lysates were harvested by centrifugation (12,000 rpm) at 48C for
30 min. Next, the protein samples (20 mg) were separated by electro-
phoresis in a 12% SDS–PAGE and were transferred onto a poly-
vinylidene fluoride membrane. The membrane was placed in 5%
nonfat milk for 1 hr to block the nonspecific binding sites and was
then incubated with a sheep anti-human VSIG1 antibody (1:1,000,
R&D Systems, Minneapolis, MN) at 48C overnight. After washing
four times in Tris-buffered saline with Tween-20, the membrane was
probed with a horseradish peroxidase (HRP)-conjugated rabbit anti-
sheep IgG antibody (1:2,000, Proteintech Group, Chicago, IL) at
378C for 60 min. After four washes, the bands were detected with
the enhanced chemiluminescence reagent (Cell Signaling Technolo-
gy, Danvers, MA). Band density was measured with ImageJ software
(National Institutes of Health, Bethesda, MD) and was standardized
to that of GAPDH detected using mouse anti-human GAPDH mono-
clonal antibody (Shanghai Kangchen, Shanghai, China).
Immunohistochemistry
After deparaffinization with dimethylbenzene, the tissue sections
were rehydrated through 100%, 95%, 90%, 80%, and 70% ethanol.
After three washes in phosphate-buffered saline (PBS), the slides
were boiled in antigen retrieval buffer containing 1 mM of disodium
ethylenediaminetetraacetic acid (pH ¼ 8.0) for 15 min in a micro-
wave oven, and the slides were then rinsed in peroxidase quenching
solution (Invitrogen) to block endogenous peroxidase. The sections
were then incubated with a sheep anti-human VSIG1 polyclonal anti-
body (1:200) at 48C overnight and then with an HRP-conjugated
rabbit anti-sheep IgG antibody (1:200) at room temperature for
30 min. Finally, 3,30-diaminobenzidine (DAB) solution was added to
the sections to develop the color, followed by counterstaining with
hematoxylin. For negative controls, adjacent sections were processed
as described above except that they were incubated overnight at 48C
in blocking solution without the primary antibody.
The intensity and extent of VSIG1 immunostaining were evaluat-
ed for all samples under double-blinded conditions. In brief, the per-
centage of positive staining was scored as 0 (0–9%), 1 (10–25%), 2
Fig. 3. VSIG1 expression in gastric epithelia and cancer tissues by immunohistochemical staining. A: Strong VSIG1 staining was observed
in noncancerous gastric mucosa. B: VSIG1-negative gastric adenocarcinoma, Grade 3, Stage T4N1M0. C: Weak VSIG1 staining in gastric
adenocarcinoma, Grade 2, Stage T3N1M0. D: Strong VSIG1 staining in gastric adenocarcinoma, Grade 2, Stage T2N1M0.
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(26–50%), or 3 (51–100%), and the intensity as 0 (no staining), 1
(weak staining), 2 (moderate staining), or 3 (dark staining). The total
score was calculated as the product of intensity and extent, ranging
from 0 to 9. The expression level of VSIG1 was defined as follow-
ing: ‘‘’’ (negative, score 0), ‘‘þ’’ (weakly positive, score 1–3),
‘‘þþ’’ (positive, score 4–6), ‘‘þþþ’’ (strongly positive, score 7–9).
Statistical Analysis
Differences in mRNA expression between cancerous and normal
gastric tissues were evaluated with the Wilcoxon signed ranks
test, whereas protein expression levels were compared with paired
Student’s t-test. A chi-squared test was used to analyze the
relationships between VSIG1 expression and various clinicopatho-
logical parameters. A Kaplan–Meier survival function was calculated
and compared with a log-rank test. A Cox proportional hazard
regression model was used for univariate and multivariate analyses
to explore the effects of the clinicopathological variables and
VSIG1 expression on survival. SPSS 17.0 software (SPSS,




We first measured VSIG1 mRNA levels in 30 paired cancerous
and normal gastric tissues using quantitative real-time PCR. As
shown in Figure 1, the median VSIG1 mRNA expression level was
significantly lower in gastric cancer tissues than the corresponding
normal gastric tissues (P ¼ 0.021), and 76% of the subjects (23/30)
displayed lower VSIG1 mRNA expression in cancer tissues.
VSIG1 Protein Expression
We then determined VSIG1 protein levels in resected gastric
cancer samples and cell lines by Western blotting. Consistent with
the quantitative real-time PCR results, out of a total of 26 paired
cancerous and adjacent normal tissues, VSIG1 expression was
reduced in cancerous tissues relative to their respective adjacent
normal tissues in 18 cases (P ¼ 0.033, Fig. 2A,B). No VSIG1
expression was detected in the 5 gastric cancer cell lines
(Fig. 2C).
Immunohistochemical Analysis of VSIG1 Expression
in Gastric Cancer and Its Relationship With the
Clinicopathological Parameters
To validate the above findings and investigate the clinicopatho-
logical and prognostic roles of VSIG1 expression, we performed
immunohistochemical analyses of the 232 paraffin-embedded
gastric cancer tissue blocks. Overall, 126 of 232 (54.3%) cases
showed negative VSIG1 expression in cancerous tissues (Fig. 3B),
whereas 106 (45.7%) cases showed positive immunostaining
(Fig. 3C,D). Normal gastric mucosa showed the strongest VSIG1
positive staining (Fig. 3A). As listed in Table I, the loss of VSIG1
expression was significantly correlated with tumor size (P ¼ 0.007),
depth of tumor infiltration (T stage, P ¼ 0.023), and distant metasta-
sis (M stage, P ¼ 0.037), but not with age, gender, tumor locus, or
local lymph node metastasis (N stage).
VSIG1 Expression and clinical Outcome
As shown in Figure 4, patients with VSIG1-negative gastric can-
cer showed shorter OS (P < 0.001, log-rank test, Fig. 4A) and
poorer DFS (P ¼ 0.006, log-rank test, Fig. 4B) than those with
VSIG1-positive gastric cancer. Univariate Cox regression analyses
revealed that OS significantly decreased with larger tumor size
(P ¼ 0.009), higher T stage (P < 0.001), higher N stage
(P < 0.001), higher M stage (P < 0.001), and negative VSIG1 ex-
pression (P < 0.001), while DFS significantly decreased with higher
T stage (P ¼ 0.047), higher N stage (P ¼ 0.016), higher M stage
(P ¼ 0.035), and negative VSIG1 expression (P ¼ 0.007; Table II).
Furthermore, multivariate Cox regression analyses confirmed T stage
(P ¼ 0.023), N stage (P < 0.001), M stage (P < 0.001), and VSIG1
expression (P ¼ 0.002) as significant independent predictors of the
OS of gastric cancer patients, whereas M stage (P ¼ 0.032) and
VSIG1 expression (P ¼ 0.039) were significant independent prog-
nostic factors for DFS (Table III).
Fig. 4. Kaplan–Meier survival curves of gastric cancer patients
(n ¼ 232) after gastrectomy. Patients with VSIG1-negative gastric
cancer showed both significantly worse OS (A) and DFS (B) than
those with VSIG1-positive gastric cancer (log-rank test, P < 0.001
and P ¼ 0.006, respectively).
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DISCUSSION
Gastric cancer remains one of the most deadly human malig-
nancies. Even with advances in diagnosis and therapy, the progno-
sis for gastric cancer is still dismal [27]. The clinical outcome of
gastric cancer is determined by local tumor growth, invasion,
and distant metastasis [3], all of which involve dysfunctional cell
adhesion [7]. Although many previous studies have addressed
the reorganization of certain adherent junction proteins, such as
the E-cadherin/b-catenin complex [8], the roles of tight junctions
in gastric cancer progression are only now beginning to be
revealed. Tight junction proteins are now considered active
regulators of cell proliferation, differentiation, migration, and gene
transcription [12].
JAMs are type I tight junction proteins characterized by two ex-
tracellular immunoglobulin (Ig)-like folds with intramolecular disul-
fide bonds, a single transmembrane domain, and a cytoplasmic
domain containing a PDZ-binding motif [12]. These proteins are
classified as C1, C2, V, and I types based on their similarity to the
constant and variable Ig regions. Although members of this protein
family have been previously studied in several kinds of malignancies
[13,14], the expression and roles of JAMs in gastric cancer are rarely
investigated, with the exception of CAR, which is expressed in all
the examined normal gastric mucosa samples (175/175), but silenced
in 87 out of the 196 (44.4%) gastric cancer samples [21]. In addition,
the expression of CAR is completely lost in KATO III and MKN38
gastric cell lines and reduced obviously in the MKN45 cell line,
whereas AGS cell line shows robust CAR expression. In this study,
we examined the mRNA and protein expression levels of VSIG1,
a V type JAM member, in paired gastric cancer tissues and nonma-
lignant gastric mucosa. Consistent with the findings of Scanlan et al.
[22] and the microarray study of Junnila et al. [23], we found that
both the mRNA and protein levels of VSIG1 were significantly lower
in cancerous tissues than the respective noncancerous mucosa. In
addition, no VSIG1 expression was detected in five gastric cancer
cell lines.
To further validate this reduction of VSIG1 expression in
gastric cancer, we performed an immunohistochemical analysis
with a sheep anti-hVSIG1 antibody. In agreement with the Western
blotting results, more than 50% of the cancer samples displayed
negative VISG1 immunostaining. Furthermore, among the VSIG1-
positive cases, most showed lower VSIG1 immunostaining relative
TABLE II. Univariate Analyses of Overall and Disease-Free Survival of Gastric Cancer Patients
Variables na
Overall survival Disease-free survival
HR 95% CI P-value HR 95% CI P-value
Age 0.144 0.194
<55 121 1.000 1.000
55 111 1.326 0.908–1.935 0.721 0.440–1.182
Gender 0.748 0.235
Female 73 1.000 1.000
Male 159 0.936 0.625–1.401 0.738 0.446–1.219
Tumor size 0.009 0.282
<3 cm 29 1.000 1.000
3 cm 203 3.000 1.316–6.840 1.539 0.702–3.374
T stage <0.001 0.047
T1 17 1.000 1.000
T2 20 2.012 0.182–22.188 3.575 0.372–34.394
T3 183 13.406 1.868–96.197 9.023 1.248–65.258
T4 12 28.014 3.494–224.629 13.979 1.554–125.759
N stage <0.001 0.016
N0 60 1.000 1.000
N1 99 3.347 1.737–6.449 2.083 1.043–4.160
N2 49 5.518 2.768–11.000 3.146 1.481–6.685
N3 24 7.972 3.743–16.981 3.365 1.292–8.761
M stage <0.001 0.035
M0 214 1.000 1.000
M1 18 6.514 3.882–10.929 2.725 1.074–6.911
Grade 0.537 0.977
1 4 1.000 1.000
2 42 6770.916 0–7.858  1048 8270.475 0–3.458  1058
3 186 9059.141 0–1.050  1049 8706.358 0–3.637  1058
Locus 0.093 0.330
Cardia and fundus 84 1.000 1.000
Corpus 36 0.854 0.501–1.455 0.855 0.410–1.782
Antrum 87 0.563 0.358–0.887 0.727 0.409–1.290
Other sitesb 25 0.928 0.481–1.790 1.474 0.688–3.160
VSIG1 <0.001 0.007
Negative 126 1.000 1.000
Positive 106 0.378 0.252–0.568 0.505 0.307–0.832
HR, hazard ratio; CI, confidence interval; VSIG1, V-set and immunoglobulin domain containing 1.
a
Numbers of cases in each group.
b
Mainly remnant gastric cancer.
Statistically significant (P < 0.05).
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to the noncancerous mucosa. Scanlan et al. [22] previously reported
a positive VSIG1 immunostaining rate of only 29% in gastric cancer
samples (5/17). This discrepancy may stem from the difference in
sample size, as our study assessed a much larger group of patients
(232 cases).
We also found that the loss of VSIG1 expression was associated
with higher T stage and larger tumor size, implying that the absence
of VSIG1 might promote tumor growth and invasion. In addition, we
detected lower VSIG1 immunostaining in stage M1 compared with
M0 gastric cancer tissues, suggesting that decreased VSIG1 expres-
sion may facilitate tumor metastasis. These findings collectively indi-
cate an important role for VSIG1 in the growth and metastasis of
gastric cancer. Whether the loss of VSIG1 is a cause or consequence
of tumor progression and metastasis, however, remains unclear. Con-
sidering that VSIG1 is a cell adhesion protein of the JAM family,
our data support the concept that disrupted intercellular adhesion is a
prerequisite for tumor growth and metastasis, in accordance with the
role described for E-cadherin in gastric cancer [28,29]. Indeed, other
JAM family members have been shown to function as tumor sup-
pressors [15]. Anders et al. [21] found that enforced ectopic expres-
sion of CAR inhibited the proliferation, migration, and invasion of
gastric cell lines, whereas RNAi-mediated CAR knockdown had op-
posite effects. Collectively, these data have suggested important bio-
logical roles of JAMs in gastric carcinogenesis.
Kaplan–Meier survival analyses revealed a significant correlation
between the loss of VSIG1 expression and poor survival of gastric
cancer patients after gastrectomy. A Cox regression model further
demonstrated that the VSIG1 expression level was an independent
risk factor for both OS and DFS, suggesting that VSIG1 may serve
as a prognostic biomarker for gastric cancer patients after surgery.
These data are in accordance with the concept of the correlation
between disturbed cell adhesion and poor prognosis in gastric cancer
[30]. In particular, it is widely accepted that the loss of E-cadherin
expression is associated with unfavorable survival in gastric cancer
patients [29]. However, only a few studies have investigated the
association between the expression of tight junction proteins,
especially the JAM family proteins, and gastric cancer prognosis.
Two previous studies reported that high expression of either claudin-
4 or claudin-18 was significantly correlated with a better prognosis
[31,32]. For JAM family members, only one report to date has corre-
lated CAR expression with the gastric cancer patient survival [21].
Our finding that the loss of VSIG1 expression in gastric cancer is
associated with more malignant phenotypes and a worse prognosis
suggests that this tight junction protein may play a tumor suppressor
role in gastric cancer cells.
VSIG1 expression is enriched in the testis, and it was reported
that the Ig domain of VSIG1 interacts with Sertoli cell membrane
protein [33]. The VSIG1 molecule belongs to the JAM family, which
contains two Ig-like domains in their extracellular area [34]. The
roles of other members of this family have been studied in breast
cancer and renal cancer [13,14]. In gastric cancer, CAR, a member
of the JAM family, has been shown to repress the proliferation, mi-
gration, and invasion of gastric cancer cells [21]. Nevertheless, there
is no report concerning the prognostic roles of VSIG1 in cancer prior
to this study. Considering the structural similarity and sequence ho-
mology of this protein family, it is possible that VSIG1 may suppress
the gastric carcinogenesis in a similar manner as CAR and JAM-A.
While our study has demonstrated a correlation between VSIG1
expression and gastric cancer stage and prognosis, the mechanism
involved in biological function of VSIG1 in gastric cancer warranties
further investigation.
CONCLUSIONS
In the present study, we report the loss of VSIG1 expression in
gastric cancers and show that the absence of this protein is correlated
with a more malignant phenotype and a worse clinical outcome. Our
findings contribute to the current understanding on the role of tight
junctions in gastric cancer. To our best knowledge, the data generat-
ed in this study represent the first report correlating the presence of
VSIG1 with clinicopathological characteristics as well as with the
OS and DFS of gastric cancer patients.
TABLE III. Multivariate Analyses of Overall and Disease-Free Survival of Gastric Cancer Patients
Variables na
Overall survival Disease-free survival
HR 95% CI P-value HR 95% CI P-value
Tumor size 0.746
<3 cm 29 1.000
3 cm 203 1.158 0.447–2.810
T stage 0.023 0.206
T1 17 1.000 1.000
T2 20 2.514 0.207–30.475 3.506 0.358–34.380
T3 183 9.456 1.147–77.978 6.431 0.861–48.031
T4 12 15.456 1.697–140.764 8.679 0.925–81.452
N stage <0.001 0.134
N0 60 1.000 1.000
N1 99 2.999 1.544–5.826 1.744 0.863–3.524
N2 49 5.214 2.560–10.622 2.506 1.159–5.418
N3 24 7.737 2.626–12.533 2.068 0.768–5.514
M stage <0.001 0.032
M0 214 1.000 1.000
M1 18 7.581 4.293–13.386 2.917 1.096–7.765
VSIG1 0.002 0.039
Negative 126 1.000 1.000
Positive 106 0.507 0.3270–.0786 0.581 0.347–0.973
HR, hazard ratio; CI, confidence interval; VSIG1, V-set and immunoglobulin domain containing 1.
a
Numbers of cases in each group.
Statistically significant (P < 0.05).
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